Cipla Ltd and Dr. Lal Pathlabs Share Q2 Results

Cipla Ltd and Dr. Lal Pathlabs Share Q2 Results

Indian Market
by 5paisa Research Team Last Updated: 2022-08-08T18:55:00+05:30

On 26th October, two important companies in the healthcare space viz. Cipla and Dr. Lal Pathlabs announced their quarterly results. Here is a gist of the numbers.
 

Cipla Ltd - Q2 Results


Cipla Ltd reported 9.56% higher sales for the Sep-21 quarter at Rs.5,520 crore. Net Profits for the Sep-21 quarter was up 6.90% at Rs.711 crore. Cipla has received a huge demand notice from the NPPA for overcharging under the DPCO. While the total demand is for Rs.3,703 crore, the matter is currently under litigation in the courts.

 

Rs in Crore

Sep-21

Sep-20

YOY

Jun-21

QOQ

Total Income (Rs cr)

₹ 5,519.80

₹ 5,038.29

9.56%

₹ 5,504.35

0.28%

Net Profit (Rs cr)

₹ 711.36

₹ 665.43

6.90%

₹ 714.72

-0.47%

Diluted EPS (Rs)

₹ 8.80

₹ 8.24

 

₹ 8.85

 

Net Margins

12.89%

13.21%

 

12.98%

 


During the quarter, Cipla did manage its raw material costs fairly well despite the supply chain constraints. However, spike in other expenses led to pressure on the profit growth. Net margins at 12.89% was lower than 13.21% on a yoy basis. Overall, the results had nothing remarkable about them in the quarter.
 

Dr. Lal Pathlabs - Q2 PAT Results


Dr. Lal Pathlabs reported 15.4% growth in sales in the Sep-21 quarter at Rs.498 crore. Net profits for the Sep-21 quarter was up by a more subdued 11.37% at Rs95cr. The board of Dr. Lal Pathlabs has approved the first dividend of 60% or Rs.6 per share on par value of Rs.10. In the first half of the financial year, the company generated 81% higher net cash from operations at Rs.282 crore.

 

Rs in Crore

Sep-21

Sep-20

YOY

Jun-21

QOQ

Total Income (Rs cr)

₹ 498.40

₹ 431.90

15.40%

₹ 606.60

-17.84%

Net Profit (Rs cr)

₹ 95.00

₹ 85.30

11.37%

₹ 131.20

-27.59%

Diluted EPS (Rs)

₹ 11.45

₹ 10.31

 

₹ 15.84

 

Net Margins

19.06%

19.75%

 

21.63%

 


With a sharp fall in COVID related testing and other medical revenues, the revenues and profits fell on a sequential basis. The profits over Sep-20 quarter grew in a more measured way because the raw material costs spiked by 25% during this period. Net margins at 19.06% was slightly lower than 19.75% in the Sep-20 quarter. 

Also Read About:- Do You know About Indian Pharma Sector?

Start Investing in 5 mins*

Get Benefits worth 2100* | Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.

Open Free Demat Account

& get benefits worth 2100*

 
Resend OTP
Please Enter OTP
  • Have Promo code?
  • Use code ACT2100
Enter Promo code

By proceeding, you agree to the T&C.

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number